Plain-English translation of NCT03518086 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative colitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a new medication designed to help people with moderate to severe ulcerative colitis whose condition had not improved with standard treatments. Researchers compared the medication to placebo (an inactive treatment) to see if this treatment could reduce symptoms and help people feel better. The study involved over 1,200 participants across multiple medical centers.
Many people with ulcerative colitis do not respond well to existing medications, or their condition stops improving over time. This trial investigated whether this medication could offer hope for patients whose disease remains active despite trying conventional or biologic therapies.
Participants received either the new medication or a placebo as an intravenous infusion (through a vein) every 4 weeks for 12 weeks, with infusions scheduled at weeks 0, 4, and 8. During this time, participants were monitored to see how well the treatment worked and whether any side effects occurred. The study evaluated whether the medication could improve symptoms of moderate to severe ulcerative colitis compared to placebo.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States